Rexulti for Schizophrenia and MDD: Is It Abilify, Round 2?
The Carlat Psychiatry Report, Volume 13, Number 9, September 2015
https://www.thecarlatreport.com/newsletter-issue/tcprv13n9/
Issue Links: Learning Objectives | Editorial Information
Topics: Antidepressants | Depressive Disorder | News of Note
On July 10, the U.S. Food and Drug Administration (FDA) approved Otsuka and Lundbeck’s Rexulti (brexpiprazole) for schizophrenia and as an add-on to antidepressants for adults with depression. As the name suggests, it’s chemically and structurally related to aripiprazole (Abilify).
You can't view details of this content, please login or buy subscription here